BIVI

BioVie Inc

Add to Watchlist

Advanced Chart

1.670

-1.24(-42.612%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

1.720

Open

1.520

VWAP

1.63

Vol

4.16M

Mkt Cap

3.10M

Low

1.520

Amount

6.80M

EV/EBITDA(TTM)

Total Shares

61.17M

-10.03M

EV/OCF(TTM)

P/S(TTM)

BioVie Inc. is a clinical-stage company developing drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders. In neurodegenerative disease, the Company’s drug candidate bezisterim (NE3107) inhibits inflammatory activation of extracellular signal-regulated kinase and the transcription factor, Nuclear factor- kB, and the associated neuroinflammation and insulin resistance but not extracellular single-regulated kinase (ERK) and nuclear factor kappa-light-chain-enhancer of activated B cells (NFkB) homeostatic functions (insulin signaling and neuron growth and survival). Both inflammation and insulin resistance are drivers of Alzheimer’s disease (AD) and Parkinson’s disease (PD). In liver disease, its orphan drug candidate BIV201 (continuous infusion terlipressin) is in the phase 3 clinical testing of BIV201 for the reduction of further decompensation in participants with liver cirrhosis and ascites.

Valuation Metrics

The current forward P/E ratio for BioVie Inc (BIVI.O) is -0.10, compared to its 5-year average forward P/E of -2.99. For a more detailed relative valuation and DCF analysis to assess BioVie Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-2.99

Current PE

-0.10

Overvalued PE

0.17

Undervalued PE

-6.15

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

0.00

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

0.00

Undervalued EV/EBITDA

0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

0.00

Current PS

0.00

Overvalued PS

0.00

Undervalued PS

0.00